Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (3608)	1/14/1998 8:38:00 PM
From: JOHN W.	Read Replies (1) of 6136

I was curious on the article you posted, I saw the exact same thing except it stopped where you have found the following additional statement by Engleberg: <<"On the other hand, we could see potential downside disappointment, just because there are new competitors coming into the market." Those competitors include a new protease inhibitor from Massachusetts-based Vertex Pharmaceuticals that could hit the market this year as well as new variations on current drugs. Additionally, some studies have suggested that patients eventually develop resistances to the protease inhibitors. Wang said analysts are looking to presentations at upcoming medical conferences, including one next month, to get a better idea of how effective the Vertex drug is. But she said Agouron could also have new data to strengthen its position, including studies of Viracept in combination with other protease inhibitors and in twice-a-day regimens, instead of the usual three doses.>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next